Morphine News and Research

Latest Morphine News and Research

Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.

2 Jun 2015

Category 1 findings support robust abuse-deterrent features of Egalet-002 for management of severe pain

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced positive top-line results from Category 1 abuse-deterrent studies for Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

1 Jun 2015

Canadian researchers shed light on molecular dynamics of chronic pain

Chronic pain affects hundreds of millions of people worldwide and is a major cause of disability, causing more disability than cancer and heart disease. Canadian researchers, including Michael Salter at SickKids are shedding light on the molecular dynamics of chronic pain. They have uncovered a critical role for a class of cells present in the brain and spinal cord, called microglia, in pain.

27 May 2015

Public health advisories reduce rate of codeine dispensed to postpartum women

Public health advisories from the U.S. Food and Drug Administration (FDA) and Health Canada were associated with significant reductions in the rate of dispensing of codeine to postpartum women, according to a study in the May 12 issue of JAMA.

14 May 2015

Scripps Florida scientists win $2.4 million to expand development of new pain therapies

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded $2.4 million from the National Institute on Drug Abuse of The National Institutes of Health to expand development of new pain medications with fewer side effects than those currently available...

8 May 2015

Egalet announces business highlights, financial results for first quarter 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today reported business highlights and financial results for the three months ended March 31, 2015.

7 May 2015

Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

A new study led by University of Toronto researcher Dr. David Lam has discovered the trigger behind the most severe forms of cancer pain. Released in top journal Pain this month, the study points to TMPRSS2 as the culprit: a gene that is also responsible for some of the most aggressive forms of androgen-fuelled cancers.

24 Apr 2015

Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

The combination of two well-known drugs will have unprecedented effects on pain management, says new research from Queen's.

8 Apr 2015

Data demonstrates benefits associated with use of EXPAREL in hip, knee replacement patients

Pacira Pharmaceuticals, Inc. today announced data demonstrating the benefits associated with the use of EXPAREL (bupivacaine liposome injectable suspension) in a study of over 2,200 hip and knee replacement patients.

27 Mar 2015

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII.

25 Mar 2015

Mesenchymal stem cell transplantation reduces opioid tolerance, opioid-induced pain

Mesenchymal stem cell (MSC) transplantation reduced opioid tolerance and opioid-induced hyperalgesia caused by daily morphine injections in rats, according to new research.

25 Mar 2015

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014.

16 Mar 2015

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

10 Mar 2015

New compound appears to play role in development of opioid tolerance

While opioids are a widely used treatment for pain, patients who take them on a regular basis can become tolerant, requiring a higher dose for continued pain relief. In a study published in Anesthesiology, the official medical journal of the American Society of Anesthesiologists, researchers identified a compound that appears to play a role in the development of opioid tolerance.

18 Feb 2015

Increasing opioid doses to manage chronic pain may intensify depression

Patients who increased doses of opioid medicines to manage chronic pain were more likely to experience an increase in depression, according to Saint Louis University findings in Pain.

16 Feb 2015

FDA accepts NDA filing for Inspirion Delivery Technologies' investigational drug, MorphaBond ER

Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.

10 Feb 2015

New compound may lead to development of potential therapeutics for neuropathic pain

A new compound discovered by a team of UC Davis investigators has potent actions against production of a chemical that which is implicated in the development of chronic pain following a peripheral nerve injury in the spinal cord.

7 Feb 2015

New multidisciplinary approach to managing colorectal operation results in shorter hospital stays, lower costs

A new multidisciplinary approach to managing patients undergoing a colorectal operation results in shorter hospital stays, fewer complications, and lower medical costs, according to research results published online in the Journal of the American College of Surgeons.

6 Feb 2015

Study could lead to potential drug treatment for fighting addiction

A research team led by the University of Colorado Boulder has discovered a mechanism in the brain that is key to making cocaine seem pleasurable, a finding that could lead to a drug treatment for fighting addiction.

5 Feb 2015

Preliminary research supports alternative drug for treating neonatal abstinence syndrome

In the past decade, the number of Kentucky babies starting life with a drug dependency, or neonatal abstinence syndrome (NAS), has skyrocketed from 1.3 per 1,000 births to 19 per 1,000 births.

4 Feb 2015

Morphine News and Research

Latest Morphine News and Research

Helsinn's Akynzeo for CINV prevention receives EC approval

Category 1 findings support robust abuse-deterrent features of Egalet-002 for management of severe pain

Canadian researchers shed light on molecular dynamics of chronic pain

Public health advisories reduce rate of codeine dispensed to postpartum women

Scripps Florida scientists win $2.4 million to expand development of new pain therapies

Egalet announces business highlights, financial results for first quarter 2015

Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

Data demonstrates benefits associated with use of EXPAREL in hip, knee replacement patients

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Mesenchymal stem cell transplantation reduces opioid tolerance, opioid-induced pain

Egalet announces net revenues of $1.9 million for 2014

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

New compound appears to play role in development of opioid tolerance

Increasing opioid doses to manage chronic pain may intensify depression

FDA accepts NDA filing for Inspirion Delivery Technologies' investigational drug, MorphaBond ER

New compound may lead to development of potential therapeutics for neuropathic pain

New multidisciplinary approach to managing colorectal operation results in shorter hospital stays, lower costs

Study could lead to potential drug treatment for fighting addiction

Preliminary research supports alternative drug for treating neonatal abstinence syndrome

Innovation in neuroscience drug discovery - eBook eBook

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Morphine News and Research

Latest Morphine News and Research

Innovation in neuroscience drug discovery - eBook eBook

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Newsletters you may be interested in